Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API

Lung Cancer Treatments and Mutations

26 та иш

  1. PD-L1 and p53 expression in squamous cell carcinoma of the oropharynx depending on human papilloma virus status

    D. Polatova, А. Yu. Madaminov, А. V. Savkin +5

    МақолаHead and Neck Cancer StudiesHead and neck tumors (HNT)20232 иқтибос
    ABI

  2. Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer

    Sunil Kumar, Sounok Sengupta, Iqra Ali +4

    МақолаQuinazolinone synthesis and applicationsJournal of Biomolecular Structure and Dynamics20231 иқтибос
    ABI

  3. Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis

    Atta Ullah Khan, Intizor Avazmetova, Mukhayya Ruzieva +4

    МақолаCancer Genomics and DiagnosticsClinical & Translational Oncology20251 иқтибос
    ABI

  4. 16 QAM trial

    M. Cronin, B. Scott

    МақолаLung Cancer Treatments and Mutations20050 иқтибос
    ABI

  5. Fostamatinib boosts QOL in RA

    МақолаChronic Myeloid Leukemia TreatmentsPharmacoEconomics & Outcomes News20110 иқтибос
    ABI

  6. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy

    Andrea Riccardo Filippi, Angela Botticella, Marilena Bellò +9

    МақолаLymphoma Diagnosis and TreatmentLeukemia & lymphoma/Leukemia and lymphoma20120 иқтибос
    ABI

  7. 130 Results of the Primary Treatment of Patients With Serous Ovarian Cancer Stage 2 in Relation to Degree of Process Differentiation

    M. Dilfuza

    МақолаOvarian cancer diagnosis and treatmentEuropean Journal of Cancer20120 иқтибос
    ABI

  8. Kanzonol-Z

    Shakhnoza S. Azimova, Valentina I. Vinogradova

    БобMelanoma and MAPK Pathways20120 иқтибос
    ABI

  9. 27P The impact of hypolipidemic drugs on course and prognosis of lung cancer

    A.S. Almanova

    МақолаCancer, Lipids, and MetabolismJournal of Thoracic Oncology20160 иқтибос
    ABI

  10. LungCARD - Report on worldwide research and clinical practices related to lung cancer

    Jankovic Radmila, Goncalves J Helena, Čavić Milena +6

    МақолаLung Cancer Treatments and MutationsZenodo (CERN European Organization for Nuclear Research)20190 иқтибос
    ABI

  11. The Value of Multiple Drug Resistance in Colorectal Cancer

    Hurshid Islamov, Navruzov Sn

    МақолаCancer, Lipids, and MetabolismEuropean Journal of Surgical Oncology20200 иқтибос
    ABI

  12. Early detection of lung cancer in Czech high-risk asymptomatic individuals (ELEGANCE)

    Lukáš Lambert, Lenka Janouskova, Matěj Novák +5

    МақолаLung Cancer Diagnosis and TreatmentMedicine20210 иқтибос
    ABI

  13. Targeted Hot Spot Sequencing of Uzbek Lung Cancer Patients

    Zebinisa Mirakbarova, Turdikulova S. H

    МақолаLung Cancer Treatments and MutationsBiomedical & Pharmacology Journal20210 иқтибос
    ABI

  14. Study of the effectiveness of chemotherapy in patients with colorectal cancer depending on the location of the metastatic lesion.

    Sergey Viktorovich Kamishov, Shakhnoza Niyozova

    МақолаColorectal Cancer Treatments and StudiesJournal of Clinical Oncology20220 иқтибос
    ABI

  15. THE IMPORTANCE OF MARKERS CK7 AND TTF-1 IN METASTATIC LUNG TUMORS

    Khamidova Farida Muinovna, BOTIROV FURKAT TASHMUHAMADOVICH, NORTOJIEV JAHONGIR MUHAMMAD OGLI +1

    МақолаCancer, Lipids, and MetabolismZenodo (CERN European Organization for Nuclear Research)20230 иқтибос
    ABI

  16. Combination of Carbonic Anhydrase Isoform IX Inhibitors and Gefitinib Suppresses on the Invasive Potential of Non-Small Cell Lung Cancer Cells

    Alexander S. Bunev, Антон А. Шетнев, Olga S. Shemchuk +9

    МақолаEnzyme function and inhibitionBiochemistry (Moscow)20240 иқтибос
    ABI

  17. Effectiveness and safety of combined therapy with pemetrexed and bevacizumab in recurrent and metastatic cervical cancer.

    Shakhnoza Niyozova, Kamila Izrailbekova, Sergey Kamishov +3

    МақолаEndometrial and Cervical Cancer TreatmentsJournal of Clinical Oncology20250 иқтибос
    ABI

  18. Exploring the GDP binding to KRas WT, G12C, G12D, G12R, and G12V and bound with MRTX1133 using steered molecular dynamics

    Abdulaziz Alamri, Showkat Ahmad Mir, Md. Shahnawaz Khan +3

    МақолаMicrotubule and mitosis dynamicsEuropean Biophysics Journal20260 иқтибос
    ABI

  19. Knowledge, Attitudes, and Screening Practices for Lung Cancer in Uzbekistan: A Nationwide Cross-Sectional Study

    Asadbek Dadaboev, Malikakhon Shukurova, Azizkhon Aziziy +2

    МақолаGlobal Cancer Incidence and ScreeningAsian Pacific Journal of Cancer Prevention20260 иқтибос
    ABI

  20. 1628 The First Comprehensive Genomic Landscape of Non-Small Cell Lung Carcinoma from Uzbekistan Reveals High TP53 Co-Mutations and Actionable Alterations in a 200-Patient Cohort

    Madina Jakhongirova, Mirzabek Shodmonov Isokul Ugli, Natalya Pak +4

    МақолаLung Cancer Treatments and MutationsLaboratory Investigation20260 иқтибос
    ABI

  21. Clinical Outcomes of EGFR-Targeted Therapy with Erlotinib Versus Polychemotherapy in NSCLC: A Statistical Analysis

    Almuradova D.M., Ravshanova . N.B, Abdurakhimov A.I.

    МақолаLung Cancer Treatments and MutationsInternational Journal of Medical Sciences And Clinical Research20260 иқтибос
    ABI

  22. Method Development And Validation For Estimation Of Related Substances In Selpercatinib Bulk Dosage Form By Rp-Hplc Technique

    Mr. Suraj P. Rajurkar, Mr. Salman Ahmad Khan, Mr. Shivprasad Sanjay Dhage +5

    МақолаChronic Myeloid Leukemia TreatmentsInternational Journal of Drug Delivery Technology20260 иқтибос
    ABI

  23. Pre-analytical standardization and multi-biofluid harmonization for liquid biopsy biomarkers in lung cancer: From discovery to clinical laboratory implementation

    Shukhrat Sharapov, Mansur Tolibov, Фарида Муиновна Хамидова +6

    МақолаLung Cancer Treatments and MutationsClinica Chimica Acta20260 иқтибос
    ABI

  24. PHARMACOLOGICAL PROPERTIES OF TYROSINE KINASE INHIBITORS: CURRENT PERSPECTIVES

    Kamola Anvarjon kizi Almirzayeva

    МақолаChronic Myeloid Leukemia TreatmentsZenodo (CERN European Organization for Nuclear Research)20260 иқтибос
    ABI

  25. PHARMACOLOGICAL PROPERTIES OF TYROSINE KINASE INHIBITORS: CURRENT PERSPECTIVES

    Kamola Anvarjon kizi Almirzayeva

    МақолаChronic Myeloid Leukemia TreatmentsZenodo (CERN European Organization for Nuclear Research)20260 иқтибос
    ABI